Biomarkers indicate cardiovascular, mortality risks in HIV
Patients wtih HIV had higher levels of all biomarkers except ST2.
HealthDay News — Specific biomarkers correlate with cardiovascular dysfunction and all-cause mortality among HIV-infected individuals, according to a study published online July 8 in JACC: Heart Failure.
Eric A. Secemsky, MD, from Massachusetts General Hospital in Boston, and colleagues examined biomarkers and electrocardiograms for 332 HIV-infected patients (median age, 49 years; 80% male) and 50 age- and gender-matched controls. The authors further assessed the correlation between biomarkers and cardiovascular dysfunction and all-cause mortality.
The researchers found that HIV patients had higher levels of all biomarkers except ST2, compared with controls. Forty-five percent of HIV patients had diastolic dysfunction (DD); ST2 correlated with DD (relative risk [RR], 1.36). Within the cohort, left ventricular systolic dysfunction was rare (5%). Twenty-seven percent of HIV patients had pulmonary hypertension, and this correlated with growth differentiation factor-15 (GDF-15; RR, 1.18), N-terminal pro-B-type-natriuretic peptide (RR, 1.18), and cystatin C (RR, 1.54). Over a median of 6.1 years there were 38 deaths in HIV subjects; all-cause mortality was independently predicted by ST2, GDF-15, high-sensitivity C-reactive protein, and D-dimer (hazard ratios, 2.04, 1.42, 1.25, and 1.49, respectively).
"Among HIV-infected individuals, ST2 and GDF-15 are associated with both cardiovascular dysfunction and all-cause mortality and may be useful at identifying those at-risk for developing cardiovascular events and death," the authors write.
Two authors disclosed financial ties to the pharmaceutical and biotechnology industries.